Additionally, on December 9, 2022 ObsEva filed a request to withdraw its previously announced moratorium with the Swiss court considering its over-indebtedness position has been resolved with the upfront proceeds of the Transaction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OBSV:
- ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
- ObsEva to increase issued share capital by creating additional treasury shares
- ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
- ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
- ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million